MARLBOROUGH, Mass. / Feb 21, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the publishing of “Making a World of Difference,” its latest annual report detailing the company’s sustainability strategy and achievements.
The report highlights how Hologic’s purpose – to enable healthier lives everywhere, every day – drives a commitment to developing medical technology innovations that generate robust financial returns. This business strength enables Hologic to invest in groundbreaking programs to increase the well-being of women, their families and their communities.
“At Hologic, we believe the best companies don’t have to choose between sustainability and maximizing performance. As you will see from the breadth and depth of our initiatives, each objective is intimately connected to our business strategy because doing the right thing is fundamental to who we are,” said Hologic Chairman, President and CEO Steve MacMillan.
Hologic’s sustainability accomplishments in the company’s fiscal year 2022 included:
In the past year, Hologic’s sustainability impact was a key reason the company received recognition from the Drucker Institute, Dow Jones, Fast Company, the Shingo Institute, LinkedIn, Newsweek, The Boston Globe and The San Diego Union-Tribune.
*Reductions compared to 2020 levels.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s sustainability efforts. There can be no assurance that these efforts will be successful, benefit the company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
| Last Trade: | US$74.91 |
| Daily Change: | -0.04 -0.05 |
| Daily Volume: | 1,226,605 |
| Market Cap: | US$16.700B |
December 16, 2025 November 25, 2025 November 03, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load